Should You Buy Stock Now in This New Coronavirus Drug Developer?
Large and small drug developers and academic researchers are furiously testing and hoping to find one or more treatments for COVID-19. While novel drugs aimed specifically at the coronavirus could potentially yield the greatest effects, the quickest route to a treatment might lie in repurposing existing drugs.
Last week, Karyopharm Therapeutics (NASDAQ: KPTI) entered the fray of drug developers seeking to find solutions for those suffering from COVID-19. It kicked off a clinical trial with Xpovio, its oral drug approved last July by the Food and Drug Administration (FDA) as a treatment for patients with relapsed or refractory multiple myeloma (a form of blood cancer).
Image Source: Getty Images.
Source Fool.com